GeneDx (WGS) Projected to Post Quarterly Earnings on Monday

Key Points

• GeneDx will report Q1 2026 results before the market opens on Monday, May 4; analysts forecast earnings of ($0.06) per share and revenue of $112.45 million, with a conference call scheduled for 4:30 PM ET.
• In the prior quarter GeneDx beat estimates with EPS of $0.14 and revenue of about $121.0 million, and analysts project roughly $1 EPS for the current fiscal year and $2 for next year while the consensus rating is a "Moderate Buy" with a $130.71 target.
• Significant insider activity: CEO Katherine Stueland sold 46,933 shares for about $2.96 million, while director Keith A. Meister purchased 140,026 shares for roughly $11.37 million, and company insiders now own about 29.6% of the stock.

GeneDx (NASDAQ:WGS - Get Free Report) is expected to be announcing its Q1 2026 results before the market opens on Monday, May 4th. Analysts expect GeneDx to post earnings of ($0.06) per share and revenue of $112.4540 million for the quarter. Interested persons may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Monday, May 4, 2026 at 4:30 PM ET.

GeneDx (NASDAQ:WGS - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a positive return on equity of 14.73% and a negative net margin of 4.92%.The firm had revenue of $120.99 million for the quarter, compared to the consensus estimate of $120.80 million. On average, analysts expect GeneDx to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

GeneDx Price Performance

GeneDx stock opened at $68.53 on Monday. The firm has a market capitalization of $2.01 billion, a P/E ratio of -91.37 and a beta of 2.17. GeneDx has a one year low of $55.17 and a one year high of $170.87. The company has a debt-to-equity ratio of 0.16, a current ratio of 2.46 and a quick ratio of 2.34. The business has a fifty day moving average price of $73.57 and a 200-day moving average price of $108.81.

Insider Transactions at GeneDx

In other news, CEO Katherine Stueland sold 46,933 shares of the company's stock in a transaction dated Thursday, March 26th. The stock was sold at an average price of $63.17, for a total value of $2,964,757.61. Following the completion of the transaction, the chief executive officer directly owned 91,514 shares in the company, valued at approximately $5,780,939.38. This represents a 33.90% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Keith A. Meister acquired 140,026 shares of GeneDx stock in a transaction dated Thursday, March 5th. The shares were purchased at an average price of $81.19 per share, for a total transaction of $11,368,710.94. Following the completion of the transaction, the director directly owned 3,228,150 shares in the company, valued at approximately $262,093,498.50. The trade was a 4.53% increase in their position. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders have sold 112,808 shares of company stock worth $8,245,748. Company insiders own 29.60% of the company's stock.

Institutional Trading of GeneDx

Several hedge funds and other institutional investors have recently bought and sold shares of WGS. Captrust Financial Advisors purchased a new position in shares of GeneDx during the fourth quarter worth approximately $244,000. MML Investors Services LLC purchased a new stake in shares of GeneDx in the 4th quarter valued at $236,000. Vontobel Holding Ltd. bought a new position in shares of GeneDx during the 4th quarter valued at $220,000. CIBC Bancorp USA Inc. bought a new position in shares of GeneDx during the 3rd quarter valued at $216,000. Finally, PharVision Advisers LLC purchased a new position in GeneDx in the 3rd quarter worth $202,000. Hedge funds and other institutional investors own 61.72% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. Weiss Ratings reissued a "sell (d)" rating on shares of GeneDx in a report on Wednesday, January 21st. Jefferies Financial Group set a $150.00 price target on GeneDx in a research report on Monday, February 23rd. Zacks Research raised shares of GeneDx from a "hold" rating to a "strong-buy" rating in a report on Wednesday, February 25th. Piper Sandler restated an "overweight" rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Finally, Canaccord Genuity Group set a $100.00 price objective on shares of GeneDx and gave the company a "buy" rating in a research note on Monday, April 20th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, GeneDx currently has a consensus rating of "Moderate Buy" and a consensus target price of $130.71.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.